TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM.
Pfaff E, et al. Among authors: rutkowski s.
J Clin Oncol. 2010 Dec 10;28(35):5188-96. doi: 10.1200/JCO.2010.31.1670. Epub 2010 Nov 8.
J Clin Oncol. 2010.
PMID: 21060032